NTT
21.5.2020 21:02:11 CEST | Business Wire | Press release
In preparation for the rescheduled 104th Indianapolis 500 presented by Gainbridge, NTT Corporation (NTT) today announced enhancements to Indianapolis Motor Speedway (IMS) that will accelerate smart technologies to improve the INDYCAR fan experience and safety when the Greatest Spectacle in Racing returns Sunday, Aug. 23, 2020.
“We are excited that when fans arrive at IMS for the Indy 500 they will be greeted with an improved, world-class and one-of-a-kind trip to the Racing Capital of the World,” said Mark Miles, Penske Entertainment Corp. President & CEO. “The future of sports will be driven by the ability to use technology to enhance fan experience, safety and convenience. NTT is helping IMS and INDYCAR find new and exciting ways to blend tradition with innovation and ultimately preserve and further The Greatest Spectacle in Racing’s history of discovery and progress.”
NTT will leverage the company’s Accelerate Smart data platform to power a 100-foot wide Media Wall at the base of the landmark Pagoda building, which will provide fans with access to data-driven race insights in real-time. The debut of the highly visible Media Wall will capture fans’ attention with 3D experiences, visualization of 143 data points from every car and multiple live feeds throughout the track. NTT’s Accelerate Smart platform will also use machine learning to indicate where cars should be on the track and predict their next move, while AI will pinpoint the best on-track battles and highlight head-to-head matchups in real-time with pit predictions, top speeds and more.
“NTT’s Accelerate Smart platform is super-charging efforts to significantly enhance the fan-experience at IMS. At this year’s Indy 500, the platform’s statistics and information will power a transformed Pagoda Plaza experience, providing key and engaging competition insights never previously available to in-venue fans in real time,” said Indianapolis Motor Speedway President, J. Douglas Boles. “In addition, NTT will also boost our safety and security grid, contributing to the well-being of spectators and event participants at the world’s largest single-day sporting event.”
At IMS, NTT’s Accelerate Smart solution includes safety and security measures that will offer more effective event security operations and oversight. Data analytics and insights will provide crowd and vehicle congestion detection and alerts that predict rates based on trends at the gates and tunnels. The digital-enabled, enhanced safety and security will establish a model to promote a consistent experience at IMS, as well as all INDYCAR venue events.
“The future of sport means providing fans with digital-first content, better access to technology and leveraging venues, such as IMS, to engage fans through new channels,” said Akira Shimada, Senior Executive Vice President, NTT. “Our Accelerate Smart data platform allows us to digitally transform INDYCAR’S fan engagement to retain its standing as a leader in motorsports, while also creating a safer race day experience.”
Penske and IMS leadership have made connectivity a key theme of investment to allow fans access to as much data and information in real-time as possible. As part of the digital focus, NTT has also evolved the INDYCAR Mobile app powered by NTT DATA to provide fans a second screen to view live in-car camera video during races, track weather forecasts, create and follow fantasy teams, watch on-demand highlights and more.
NTT’s is committed to accelerating the future of smart racing and creating the next generation of INDYCAR fans who want to enjoy the sport through a more digital experience. This is in part why NTT, a global information technology and communications leader, has been the title sponsor of the NTT INDYCAR SERIES since 2019, as well as the Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway, Indianapolis 500 and NASCAR’s the Brickyard 400.
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005270/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom